XML 30 R11.htm IDEA: XBRL DOCUMENT
v3.20.4

Revenues | 12 Months Ended
--- | ---
Dec. 31, 2020
Revenues [Abstract] |
Revenues | Revenues Product Revenues The Company’s net product revenues consisted of the following for the years ended December 31:
|  | 2020 |  | 2019 |  | 2018
Products: |  |  |  |  |  |
Kristalose |  | $ | 15,567,562 |  |  | $ | 12,895,120 |  |  | $ | 12,055,625 |
Vibativ |  | 10,870,990 |  |  | 8,691,550 |  |  | 5,075,057 |
Caldolor |  | 5,336,943 |  |  | 5,222,282 |  |  | 5,001,997 |
Acetadote |  | 1,874,206 |  |  | 3,824,449 |  |  | 4,284,111 |
Omeclamox-Pak |  | 257,088 |  |  | 837,829 |  |  | 623,297 |
Vaprisol |  | 1,077,227 |  |  | 936,615 |  |  | 1,763,874 |
RediTrex |  | 856,657 |  |  | — |  |  | — |
Total net product revenues |  | $ | 35,840,673 |  |  | $ | 32,407,845 |  |  | $ | 28,803,961 |
Other Revenues During 2019, Cumberland executed a License and Distribution agreement with HongKong WinHealth Pharma Group Co. Limited (“WinHealth”) for our Caldolor and Acetadote brands in China and Hong Kong. In conjunction with these new arrangements, the Company terminated a previous License and Distribution agreement with Gloria Pharmaceuticals Co ("Gloria Pharmaceuticals") for the two brands. In addition, we also signed a new License and Distribution agreement with DB Pharm Korea Co., Ltd. (“DB Pharm”) for Vibativ in South Korea. As a result of these agreements, Cumberland recognized approximately $0.3 million of non-refundable up-front payments as other revenue in the consolidated statement of operations during 2019. There were no payments received in 2020. The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner’s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies. The contractual payments associated with the partner’s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period. The international agreements provide for $1.0 million in non-refundable up-front payments, milestone payments of up to $2.2 million related to regulatory approvals and up to $4.8 million in payments related to product sales. From 2012 through December 31, 2020, the Company has recognized a cumulative $1.2 million in upfront payments as other revenue and has recognized $0.1 million in revenue related to the milestone payments associated with these international agreements. Other revenues during 2020, 2019 and 2018 also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET’s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.8 million, $1.3 million, and $0.1 million for the years ending December 31, 2020, 2019 and 2018, respectively.

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenuesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration